Advanced search
Publication Cover
Expert Review of Hematology Volume 13, 2020 - Issue 4
Submit an article Journal homepage
10,132
Views
30
CrossRef citations to date
0
Altmetric
Original Research

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

Ajai ChariDepartment of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0405-7480View further author information
ORCID Icon,
Paul G. RichardsonJerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Dorothy RomanusGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Meletios A. DimopoulosHematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0001-8990-3254View further author information
ORCID Icon,
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-0808-2237View further author information
ORCID Icon,
Evangelos TerposHematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0001-5133-1422View further author information
ORCID Icon,
Roman HajekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicView further author information
,
Aditya RajuScientific Consulting, Xcenda, Palm Harbor, FL, USAView further author information
,
Antonio PalumboGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Lauren E. CainGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Marlo BlazerScientific Consulting, Xcenda, Palm Harbor, FL, USAView further author information
,
Hui HuangGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Eileen FarrellyScientific Consulting, Xcenda, Palm Harbor, FL, USAView further author information
&
Sikander AilawadhiDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United StatesCorrespondence[email protected]
View further author information
 show all
Pages 421-433 | Received 17 Jan 2020, Accepted 11 Feb 2020, Published online: 09 Mar 2020

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Enrique M. Ocio, Omar Nadeem, Fredrik Schjesvold, Francesca Gay, Cyrille Touzeau, Meletios A. Dimopoulos, Paul G. Richardson & Maria-Victoria Mateos. (2022) Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology 15:4, pages 371-382.
Read now
Patricio Jose Duarte, Natalia Paola Schutz, Paola Ochoa, Sebastian Yantorno, Sergio Orlando, Sergio Lopresti, Soledad Zabaljauregui, Florencia Aizpurua, Claudia Shanley, Elvira Giannini, Gonzalo Garate, Cecilia Foncuberta, Jorge Milone, Dardo Riveros & Dorotea Fantl. (2021) Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple. Expert Review of Hematology 14:3, pages 315-322.
Read now

Articles from other publishers (28)

Larysa SanchezAjai ChariMu ChengDasha CherepanovMaral DerSarkissianFei HuangDawn Marie StullJonathan DaboraMelanie YoungStephen J. NogaSelina PiMelody ZhangAzeem BanatwalaMei Sheng DuhSikander Ailawadhi. (2023) Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Journal of Managed Care & Specialty Pharmacy 29:11, pages 1205-1218.
Crossref
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, Kosei Matsue, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Takahiro Maeda, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki & Shinsuke Iida. (2023) A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Annals of Hematology.
Crossref
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki, Hiroshi Handa, Takaaki Chou, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki & Kenshi Suzuki. (2023) Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma. Annals of Hematology 102:9, pages 2493-2504.
Crossref
Irit Avivi, Naama Yekutiel, Tamir Shragai, Yael C. Cohen, Moshe Grunspan, Noa Rivlin, Neta Frankel, Raanan Cohen, Clara Weil & Gabriel Chodick. (2023) Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studies. Annals of Hematology.
Crossref
M. Macro, C. Hulin, L. Vincent, A. Charvet-Rumpler, L. Benboubker, C. Calmettes, A.-M. Stoppa, K. Laribi, L. Clement-Filliatre, H. Zerazhi, F. Honeyman, V. Richez, F. Maloisel, L. Karlin, J. Barrak, C. Chouaid & X. Leleu. (2023) Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study. Annals of Hematology 102:8, pages 2137-2151.
Crossref
Ji Hyun Lee, Sung-Hyun Kim, Hye Ryeon Kim, Chang-Ki Min, Je-Jung Lee, Ho-Jin Shin, Jae-Cheol Jo, Ji Yun Lee, Joon Ho Moon & Kihyun Kim. (2022) Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. International Journal of Hematology 117:2, pages 225-235.
Crossref
Sikander Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, Dasha Cherepanov, Bridgette Kanz Schroader, Dorothy Romanus, Eileen Farrelly & Ajai Chari. (2022) Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer Medicine 12:3, pages 3145-3159.
Crossref
Helan Kurian, Suja Abraham, Arpith Antony, Jeeva Ann Jiju & Timy Thomas. (2023) Multiple myeloma: Unveiling the survival data with different lines of treatments. Journal of Cancer Research and Therapeutics 19:3, pages 720-724.
Crossref
V.L. Ostrovskyi, I.M. Skrypnyk, G.S. Maslova, O.A. Shaposhnyk & L.I. Yakymyshyna. (2022) PECULIARITIES OF MYOCARDIAL BIOELECTRIC ACTIVITY IN PATIENTS WITH PROGRESSIVE MYLTIPLE MYELOMA RECEIVING BORTEZOMIB-CONTAINING CHEMOTHERAPY SCHEMES. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 22:3-4, pages 80-84.
Crossref
Ajay Major, Andrzej Jakubowiak & Benjamin Derman. (2022) Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e1000-e1008.
Crossref
Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Pospisilova, Petra Krhovska, Denisa Novakova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Vladimir Maisnar & Roman Hajek. (2022) Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers 14:20, pages 5165.
Crossref
Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti, Francesca Fazio, Roberto Mina, Magda Marcatti, Anna Cafro, Renato Zambello, Laura Paris, Gregorio Barilà, Cecilia Olivares, Alessandra Pompa, Rita Mazza, Francesca Farina, Martina Soldarini, Pietro Benvenuti, Giuseppina Pagani, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Catherine Klersy, Luca Arcaini & Maria Teresa Petrucci. (2022) Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. Haematologica 108:3, pages 833-842.
Crossref
Richard LeBlanc, Hira Mian, Donna Reece, Esther Masih‐Khan, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha Louzada, Darrell White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Engin Gul & Christopher P. Venner. (2022) Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. British Journal of Haematology 198:1, pages 93-102.
Crossref
Luca Bertamini, Giuseppe Bertuglia & Stefania Oliva. (2022) Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. Frontiers in Oncology 12.
Crossref
Iulia Bujoreanu, Chris Hogan & Jagdeep S. Virk. (2020) Multiple Upper Aerodigestive Tract Masses Presenting With Stridor—A Rare Case of Aggressive Multifocal Extramedullary Plasmacytoma. Ear, Nose & Throat Journal 101:3, pages 186-188.
Crossref
Yuka Kawaji-Kanayama, Ayako Muramatsu, Nana Sasaki, Kazuho Shimura, Miki Kiyota, Shinichi Fuchida, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Yoshiaki Chinen, Shinsuke Mizutani, Mitsushige Nakao, Hiroto Kaneko, Eri Kawata, Koichi Hirakawa, Ryoichi Takahashi, Chihiro Shimazaki, Hitoji Uchiyama, Nobuhiko Uoshima, Yuji Shimura, Tsutomu Kobayashi, Masafumi Taniwaki & Junya Kuroda. (2022) Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. International Journal of Hematology 115:3, pages 350-362.
Crossref
José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso & Juan-José Lahuerta. (2022) The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomarker Research 10:1.
Crossref
Karen Louise Højholt, Henrik Gregersen, Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen & Annette Juul Vangsted. (2021) Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients. Hematological Oncology 39:4, pages 521-528.
Crossref
Faith Davies, Robert Rifkin, Caitlin Costello, Gareth Morgan, Saad Usmani, Rafat Abonour, Antonio Palumbo, Dorothy Romanus, Roman Hajek, Evangelos Terpos, Dasha Cherepanov, Dawn Marie Stull, Hui Huang, Xavier Leleu, Jesus Berdeja, Hans C. Lee, Katja Weisel, Michael Thompson, Mario Boccadoro, Jeffrey Zonder, Gordon Cook, Noemi Puig, Jorge Vela-Ojeda, Eileen Farrelly, Aditya Raju, Marlo Blazer & Ajai Chari. (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology 100:9, pages 2325-2337.
Crossref
Thierry FaconChristopher P. VennerNizar J. BahlisFritz OffnerDarrell J. WhiteLionel KarlinLotfi Benboubker, Sophie RigaudeauPhilippe RodonEric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan ZhangPhilip Twumasi-AnkrahGodwin Yung, Robert M. RifkinPhilippe MoreauSagar LonialShaji K. Kumar, Paul G. Richardson & S. Vincent Rajkumar. (2021) Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137:26, pages 3616-3628.
Crossref
Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Evangelos Terpos & Meletios A. Dimopoulos. (2021) Real-World Treatment of Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma Myeloma and Leukemia 21:6, pages 379-385.
Crossref
Roman Hájek, Jiří Minařík, Jan Straub, Luděk Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Bařinová, Matyáš Kuhn, Jiří Šilar, Lenka Čápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar. (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology.
Crossref
Evangelos Terpos, Joseph Mikhael, Roman Hajek, Ajai Chari, Sonja Zweegman, Hans C. Lee, María-Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gordon Cook, Katja C. Weisel, Caitlin L. Costello, Jennifer Elliott, Antonio Palumbo & Saad Z. Usmani. (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal 11:2.
Crossref
Serena Rocchi, Paola Tacchetti, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Chiara di Giovanni Bezzi, Marco Scalese, Luca Dozza, Giulia Marzocchi, Marina Martello, Gregorio Barilà, Elisabetta Antonioli, Michela Staderini, Gabriele Buda, Mario Petrini, Michele Cea, Micol Quaresima, Anna Furlan, Angela Bonalumi, Michele Cavo & Elena Zamagni. (2020) A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematological Oncology 39:1, pages 41-50.
Crossref
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, Dasha Cherepanov, Brittany Demers, Vickie Lu, Presley Whidden, Suman Kambhampati, Ruemu E. Birhiray, Haresh S. Jhangiani, Ralph Boccia & Robert M. Rifkin. (2020) Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma and Leukemia 20:11, pages e910-e925.
Crossref
Hira S. Mian, Hsien Seow, Tanya M. Wildes, C. Tom Kouroukis, Gregory R. Pond, Branavan Sivapathasundaram & Jonathan Sussman. (2020) Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology.
Crossref
Ada Hang-Heng Wong, Eun Myoung Shin, Vinay Tergaonkar & Wee-Joo Chng. (2020) Targeting NF-κB Signaling for Multiple Myeloma. Cancers 12:8, pages 2203.
Crossref
Gordon Cook, A John Ashcroft, Guy Pratt, Rakesh Popat, Karthik Ramasamy, Martin Kaiser, Matthew Jenner, Sarah Henshaw, Rachel Hall, Jonathan Sive, Simon Stern, Matthew Streetly, Ceri Bygrave, Richard Soutar, Neil Rabin & Graham H Jackson. (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology 190:2.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.